Modified low-dose triamcinolone acetonide intravitreal injection for macular cystoid edema after cataract surgery

• Main Authors: Hai-Xiao Feng, Yan-Fen Wang, Yu-Ping Zheng, Feng Wang, Ling Bai
• Format: Article
• Language: English
• Published: Press of International Journal of Ophthalmology (IJO PRESS) 2019-11-01
• Series: Guoji Yanke Zazhi
• Subjects: pseudophakic cystoid macular edema; triamcinolone acetonide; intravitreal injection
• Online Access: http://ies.ijo.cn/cn_publish/2019/11/201911036.pdf

AIM:To investigate the efficacy of intravitreal injection of modified low-dose of triamcinolone acetonide(TA)in the treatment of pseudophakic cystoid macular edema(PCME).<p>METHODS: Retrospective study. Totally 12 eyes of 12 patients with PCME in our hospital were received intravitreal injection with modified low doses of TA from 2015-01 to 2018-12. The TA suspension was firstly resuspended by intraocular irrigating solution through 0.22um pore filter, then the new TA suspension(2mg/0.05mL)was injected intravitreally. The best-corrected visual acuity(BCVA), central macular thickness(CMT), intraocular pressure(IOP), and other side effects were recorded at 2wk, 1mo, 3mo and 6mo after injection, then compared the data with pre-injection(baseline)information.<p>RESULTS: After intravitreal injection of modified low dose TA, all patients got improved BCVA and alleviated CMT, as compare to the baseline data, and the difference was statistically significant(<i>P</i><0.05), but the difference of IOP was not significant(<i>P</i>>0.05). All patients had no recorded ocular or systemic complication.<p>CONCLUSION: Intravitreal injection of modified low-dose TA is effective and safe for PCME, without significant increase in IOP. It's an affordable substitution to anti-vascular endothelial growth factor(anti-VEGF)agents. This still needs to be confirmed by the long-term follow-up study with large samples.